620
Participants
Start Date
December 30, 2022
Primary Completion Date
December 1, 2025
Study Completion Date
December 1, 2026
PIK3CA inhibitor
PIK3CA inhibitor
AKT inhibitor
AKT inhibitor
Carrelizumab
Pd-1 mab
Famitinib
VEGFR inhibitor
Fluzoparib
PARP inhibitor
Dalpiciclib
CDK4/6 inhibitor
SHR-A1811
HER2 ADC
Everolimus
mTOR inhibior
Aromatase Inhibitors or Fulvestrant
Letrozole/Anastrozole/Exemestane or Fulvestrant
Goserelin
For premenopause
TPC
Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
Sorafenib
RTK Inhibitor
Apatinib
Apatinib 250mg po qd
SHR-A1921
TROP2 ADC
SHR-A2102
NECTIN4 ADC
SHR-A2009
HER3 ADC
SHR-1167
PARP1i
SHR-6209
CDK4i
bevacizumab
bevacizumab
RECRUITING
Breast cancer institute of Fudan University Cancer Hospital, Shanghai
Peking University Cancer Hospital & Institute
OTHER
First Hospital of China Medical University
OTHER
Sun Yat-sen University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Chongqing University Cancer Hospital
OTHER
Northern Jiangsu People's Hospital
OTHER
Fujian Medical University Union Hospital
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Shanghai First Maternity and Infant Hospital
OTHER
Shanghai 6th People's Hospital
OTHER
Affiliated Hospital of Nantong University
OTHER
Nanchang People's Hospital
UNKNOWN
Liaoning Cancer Hospital & Institute
OTHER
The Affiliated Hospital of Nantong University
UNKNOWN
The First Hospital of Jilin University
OTHER
Fudan University
OTHER